Residency · Sacramento, CA
Sponsored by University of California Davis Health
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2023 · 555 citations · Richard Valicenti
NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024.
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · 260 citations · Richard Valicenti
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.
Journal of the National Comprehensive Cancer Network : JNCCN · 2023 · 289 citations · Dominique Rash
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026.
Journal of the National Comprehensive Cancer Network : JNCCN · 2026 · 33 citations · Dominique Rash
Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2025 · 84 citations · Richard Valicenti
NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.
Journal of the National Comprehensive Cancer Network : JNCCN · 2022 · 247 citations · Richard Valicenti
Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion.
Nature communications · 2022 · 227 citations · Ruben Fragoso, Arta Monjazeb
Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?
Journal for immunotherapy of cancer · 2021 · 267 citations · Arta Monjazeb